Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest reaches new heights on growing drug sales
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
FAST NEWS: Everest Medicines loss widens on drug commercialization
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
